Exor N.V. has recently filed an amended 13F report, which highlights new holdings and a total asset value of over $28.9 billion. This filing is significant as it provides insights into Exor's investment strategy and its positions in various sectors, particularly in automotive and luxury goods.
Exor N.V. is an investment company based in Amsterdam, Netherlands. It operates under the Central Index Key (CIK) number 0001589122. The company is recognized for its strategic investments across various industries, particularly in the automotive sector. The recent filing is part of a series of recent 13F reports, indicating active management of its investment portfolio.
The amended filing, submitted on November 13, 2026, reflects changes as of December 31, 2024. It includes new holdings that could potentially reshape Exor's investment landscape. The report states, "This is an amendment to the previous filing to include new holdings." This suggests that Exor is actively adjusting its portfolio to align with market conditions and opportunities.
This update may affect various stakeholders, including investors and analysts who track Exor's portfolio for trends in investment strategies. The automotive and luxury goods sectors may see increased scrutiny as Exor's significant stakes in companies like Ferrari N.V. and Stellantis N.V. come to light. These holdings could influence market perceptions and investment decisions within these industries.
Looking ahead, it remains unclear what specific actions Exor will take following this filing. The filing does not specify any upcoming votes or further disclosures. Investors and analysts will likely be watching closely for any additional updates or strategic moves from Exor N.V.
Read Next
Jensen Quality Growth Fund adds Tyra S. Pratt as manager
FT 13353 Files Definitive Letter Certifying Registration Amendment
FT 13354 confirms registration statement amendment filing
FT 13365 Confirms Compliance with SEC Regulations
FTP 11 files definitive letter on registration statement amendment
Aptevo Therapeutics schedules special stockholder meeting





